GleamWall
中文EN

ELAN Elanco Animal Health Inc

Pharmaceutical Preparations · NYSE · SEC CIK 1739104 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY12.1%
TTM net income YoY-508.3%
TTM EPS YoY-528.6%
Revenue 3-yr CAGR5.7%
Net income 3-yr CAGR—

Margins

Gross margin56.2%
Operating margin—
Net margin-2.9%
FCF margin7.9%
EBITDA margin—

Returns

ROE-2.2%
ROA-1.1%
ROIC (approx.)—
Asset turnover0.38x

Leverage & solvency

Liabilities / assets50.3%
Debt / equity0.56x
Current ratio2.09x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-4.18x
Accruals ratio-5.7%
Payout ratio—
Capex / revenue4.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.26B$1.37B$1.37B$1.14B$1.14B$1.24B$1.19B$1.02B
Cost of revenue$545.00M$570.00M$586.00M$555.00M$530.00M$528.00M$509.00M$501.00M
Gross profit$720.00M$798.00M$785.00M$589.00M$607.00M$713.00M$684.00M$519.00M
R&D expense$99.00M$92.00M$97.00M$93.00M$89.00M$92.00M$94.00M$81.00M
SG&A expense$393.00M$449.00M$381.00M$338.00M$351.00M$400.00M$341.00M$300.00M
Pretax income$24.00M$56.00M$87.00M-$259.00M-$50.00M$25.00M$60.00M-$51.00M
Income tax$6.00M$2.00M$30.00M$17.00M-$16.00M$14.00M-$7.00M-$43.00M
Net income$18.00M$54.00M$57.00M-$276.00M-$34.00M$11.00M$67.00M-$8.00M
EPS (basic)0.040.110.11—-0.070.020.14—
EPS (diluted)0.040.110.11—-0.070.020.13—
Weighted avg. shares (diluted)506.50M505.90M506.00M—496.80M500.10M499.10M—
Balance sheet
Cash & equivalents$465.00M$530.00M$428.00M$545.00M$505.00M$539.00M$487.00M$468.00M
Receivables$992.00M$1.08B$1.08B$873.00M$894.00M$989.00M$970.00M$805.00M
Inventory$1.82B$1.77B$1.72B$1.74B$1.71B$1.67B$1.59B$1.57B
Current assets$3.73B$3.80B$3.58B$3.46B$3.49B$3.61B$3.44B$3.21B
PP&E, net$1.44B$1.41B$1.40B$1.41B$1.39B$1.36B$1.05B$993.00M
Goodwill$4.80B$4.84B$4.72B$4.78B$4.76B$4.76B$4.51B$4.41B
Intangibles$3.03B$3.20B$3.23B$3.41B$3.60B$3.71B$3.63B$3.68B
Total assets$13.34B$13.56B$13.22B$13.36B$13.55B$13.74B$12.94B$12.61B
Current liabilities$1.79B$1.85B$1.66B$1.60B$1.46B$1.39B$1.27B$1.31B
Short-term debt$74.00M$73.00M$73.00M$74.00M$62.00M$61.00M$44.00M$44.00M
Long-term debt$3.63B$3.85B$3.92B$3.94B$3.96B$4.15B$4.35B$4.28B
Total debt$3.71B$3.92B$3.99B$4.02B$4.02B$4.21B$4.39B$4.32B
Total liabilities$6.71B$6.97B$6.72B$6.81B$6.80B$6.97B$6.59B$6.52B
Shareholders' equity$6.63B$6.59B$6.50B$6.55B$6.75B$6.78B$6.35B$6.10B
Net debt$3.24B$3.39B$3.56B$3.47B$3.52B$3.67B$3.91B$3.85B
Shares outstanding499.73M499.55M499.38M496.98M496.83M496.65M496.46M494.45M
Cash flow statement
Operating cash flow$216.00M$277.00M$13.00M$108.00M$219.00M$237.00M-$4.00M$177.00M
Capital expenditure$60.00M$33.00M$51.00M$62.00M$92.00M$57.00M$65.00M$47.00M
Free cash flow$156.00M$244.00M-$38.00M$46.00M$127.00M$180.00M-$69.00M$130.00M
Investing cash flow-$62.00M-$110.00M-$60.00M-$64.00M-$101.00M-$56.00M-$58.00M-$90.00M
Financing cash flow-$216.00M-$74.00M-$65.00M-$18.00M-$153.00M-$156.00M$52.00M-$32.00M
Depreciation & amortization$27.00M$26.00M$172.00M$174.00M$28.00M$25.00M$161.00M$164.00M
Stock-based compensation$20.00M$20.00M$21.00M$16.00M$17.00M$20.00M$15.00M$15.00M

Free plan shows the latest 8 periods; Pro shows all 39 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.